Introduction Transgender individuals are at risk for HIV. HIV risks are dynamic and there
have been substantial changes in HIV prevention (eg, pre-exposure prophylaxis [PrEP]). It is …

Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first
approved by the US Food and Drug Administration in 2012. Despite correlations of …

Abstract Black and Hispanic/Latinx transgender women in the United States (US) are
disproportionately affected by HIV. Pre-exposure prophylaxis (PrEP) reduces risk of HIV …

Objectives HIV pre‐exposure prophylaxis (PrEP) delivery in the UK is inequitable; over 95%
of PrEP users were men who have sex with men (MSM) despite making up less than 50% of …

CDC recommends pre-exposure prophylaxis (PrEP) for transgender women who have sex
with men and who report sexual behaviors that place them at substantial ongoing risk for …

The purpose of this qualitative study was to identify barriers and motivators to PrEP uptake
from the perspective of Black and Latina transgender women (TW) who are currently using …

Abstract In the United States, a context of multiple marginalization shapes sexual health
disparities experienced by transgender women. Using data from 396 transgender women …

This study aimed to identify factors associated with HIV risk perception among Mexican
transgender women (TGW). This cross-sectional survey was conducted online and at a …

China's national guidelines call for increasing HIV pre-exposure prophylaxis (PrEP) use to
reverse the epidemic in populations at highest risk. However, few data exist on PrEP …

Background Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) was approved
by the US Food and Drug Administration in December 2021. This initial phase of …